Trial Profile
A Phase 1b Study of Weekly Paclitaxel With Ramucirumab (IMC-1121B) Drug Product in Patients With Advanced Gastric Adenocarcinomas.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 May 2016
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Paclitaxel
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 09 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 09 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Sep 2011 Planned end date changed from Aug 2011 to Nov 2011 as reported by ClinicalTrials.gov.